Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date16 Jul 2020 |
A randomized, double-blind, placebo-controlled, multicenter clinical trial for the effectiveness and safety of Xuechang Shuxuening injection in the treatment of acute ischemic stroke
A randomized, double-blind, placebo-controlled, multicenter clinical trial for the effectiveness and safety of Shuxuening injection in the treatment of unstable angina
100 Clinical Results associated with CSPC Yinhu Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with CSPC Yinhu Pharmaceutical Co., Ltd.
100 Deals associated with CSPC Yinhu Pharmaceutical Co., Ltd.
100 Translational Medicine associated with CSPC Yinhu Pharmaceutical Co., Ltd.